Cumulative incidence of ICH in patients with metastatic brain tumors. No difference in (A) the cumulative incidence of total and (B) significant ICH (>10 mL, symptomatic, or necessitating neurosurgery) was found in cancer patients with brain metastases when the control group (blue) was compared with patients treated with enoxaparin (red). See Figure 1B-C in the article by Donato et al that begins on page 494.